Showing results (81-90 of 109) with videos related to
Sort By:
Pageof 11
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Primary resistance to ICI-based regimens is associated with early longitudinal changes in the fecal microbiome and loss of microbial stabilityYujie Zhao, Jarushka Naidoo, Michael Conroy, et al.The New England Journal of Medicine|January 5, 2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced MelanomaHussein A Tawbi, Dirk Schadendorf, Evan J Lipson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2020
The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal MelanomasAlvin P Makohon-Moore, Evan J Lipson, Jody E Hooper, et al.Journal for Immunotherapy of Cancer|August 12, 2021
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkersJarushka Naidoo, Karisa C Schreck, Wei Fu, et al.Cancer Immunology Research|March 27, 2025
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 CytokinesMari Nakazawa, Soren Charmsaz, Elsa Hallab, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2017
Transcriptional Mechanisms of Resistance to Anti-PD-1 TherapyMaria L Ascierto, Alvin Makohon-Moore, Evan J Lipson, et al.Cell|September 7, 2024
Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapyYash Chhabra, Mitchell E Fane, Sneha Pramod, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2023
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.Cancer Immunology Research|June 26, 2026
Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumorsHoward L Li, Soren Charmsaz, Chester Kao, et al.Pageof 11